Explain this page
Arphra AIPlain-English read on Adaptive Biotechnologies Corporation’s valuation06-12today
- Adaptive Biotechnologies Business Separation May Unlock Greater Value7d
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering8d
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering8d
- Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses8d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$2.27
-88.27% vs spot
Recommendation
Sell
5 of 5 methods
Method spread
0bull5bear
±5% threshold
Analyst PT consensus: $21.33 (+10.29%)
Candlestick · 1Y
Open in chart workstation →ADPT
17.53-4.68%H 19.80L 12.00MA50 14.42MA200 —Avg vol 2.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +12.25% | +10.51% | +36.87% | +36.68% | +15.81% | +19.09% | +61.44% | +187.37% | -52.14% | -52.01% | -52.01% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$95K
1 txn
Net flow
−$95K
Aftermarket
LiveLast trade
$19.50
55 sh
Bid
$18.75
5 sh
Ask
$19.50
1 sh
Spread
$0.750
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $71.68M | -$13.58M | $-0.09 |
| Q3 Sep 2025 | $93.97M | $9.55M | $0.06 |
| Q2 Jun 2025 | $58.88M | -$25.61M | $-0.17 |
| Q1 Mar 2025 | $52.44M | -$29.85M | $-0.20 |
| Q4 Dec 2024 | $47.46M | -$33.69M | $-0.23 |
| Q3 Sep 2024 | $46.44M | -$32.07M | $-0.22 |
Sector & industry today
LiveSectors
- Consumer Cyclical+1.37%
- Technology+1.17%
- Utilities+0.96%
- Financial Services+0.65%
- Basic Materials+0.59%
- Industrials+0.54%
- Consumer Defensive+0.42%
- Energy-0.18%
- Communication Services-0.40%
- Healthcare-0.41%
- Real Estate-0.54%
Top industries (issuer's industry highlighted)
- Biotechnology+9.63%
- Software - Services-7.11%
- Business Equipment & Supplies+6.51%
- Financial - Mortgages+4.52%
- Furnishings, Fixtures & Appliances+4.34%
- Home Improvement+3.89%
- Construction+3.62%
- Paper, Lumber & Forest Products+3.53%
- Discount Stores+3.53%
- Medical - Diagnostics & Research+3.31%
- Financial - Conglomerates+3.03%
- REIT - Hotel & Motel+2.92%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Adaptive Biotechnologies Business Separation May Unlock Greater Valuebenzinga.com·Jun 17, 2026
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offeringglobenewswire.com·Jun 17, 2026
- Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offeringglobenewswire.com·Jun 17, 2026
- Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businessesbenzinga.com·Jun 16, 2026
- Adaptive Biotechnologies plans separation of immune medicine platformreuters.com·Jun 15, 2026
- Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businessesglobenewswire.com·Jun 15, 2026
- Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businessesglobenewswire.com·Jun 15, 2026
- Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offeringglobenewswire.com·Jun 15, 2026
Recent analyst activity
DB- Jun 17, 2026GradeBuy → BuyBTIG Reiterates Buy Rating on Adeptus Biotechnologies Corp. (ADPT)BTIG
Peers
No peer list available for ADPT.
Total assets
$512.74M
Total debt
$280.58M
Cash & equiv
$70.5M
Operating CF
-$45.99M
Free cash flow
-$48.95M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
BOBULSKY SUSAN officer: Chief Commercial Officer, MRD | Sell | 5,000 | $95K | Jun 11, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $276.98M | -$57.12M | -$59.5M | $-0.39 | -21.48% |
| FY 2024 | $178.96M | -$162.55M | -$159.49M | $-1.08 | -89.12% |
| FY 2023 | $170.28M | -$227.04M | -$225.25M | $-1.56 | -132.29% |
| FY 2022 | $185.31M | -$200.19M | -$200.19M | $-1.00 | -108.03% |
| FY 2021 | $154.34M | -$208.97M | -$207.28M | $-1.46 | -134.30% |